SCH 58261

SKU: orb1300293

Description

SCH 58261

Research Area

Neuroscience, Pharmacology & Drug Discovery

Key Properties

• CAS Number: 160098-96-4
• MW: 345.36
• Purity: 99.75%
• Formula: C₁₈H₁₅N₇O
• SMILES: Nc1nc2n(CCc3ccccc3)ncc2c2nc(nn12)-c1ccco1
• Target: Adenosine Receptor
• Solubility: DMSO:34.5 mg/mL (99.9 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (5.79 mM)

Bioactivity

• Target IC50:
  A2a (bovine):2.0 nM(Ki)|A2A (rat):2.3 nM(Ki)
• In Vivo:
  In mice with Spinal cord injury, SCH58261 (0.01 mg/kg, i.p.) reduces demyelination and levels of TNF-α, Fas-L, PAR, Bax expression and activation of JNK MAPK. Chronic SCH58261 administration improves the neurological deficit up. In rats with 6-OHDA-induced Parkinson's disease, SCH58261 (2 mg/kg, i.p.) improves the 6-OHDA-induced bradykinesia and motor disturbance.
• In Vitro:
  SCH 58261 causes the inhibition of rabbit platelet aggregation and porcine coronary artery relaxation by antagonizing competitively the effects induced by CGS 21680.

Storage & Handling

• Storage: store at low temperature,keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Adenosine Receptor, AdenosineReceptor, A2A (bovine), A2A (rat), Inhibitor, P1 receptor, inhibit, SCH58261, SCH-58261, SCH 58261

Compound Identifiers

PubChem CID

176408